Zonagen (zona) - good buy? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Myron David Kor who wrote (656)	10/16/1997 12:05:00 AM
From: Cacaito	of 7041

From the 1996 Zonagen Annual Report: "The Company's issued patent and patent application relating to Vasomax TM are method of use patents that cover the use of certain compounds to treat specified conditions rather than composition of matter patents" They do not have the patent on the "composition of matter" because phentolamine the chemical has been off patent for long time. The "method of use" "for certain conditions" is the actual oral form that Zona is working on. This is like Vivus patent, PGE1 the chemical is off patent, but the method "transuretrhal" is the patent. HVSF is developing a "transurethral" delivery: will Vivus prevail? I will not count on that but the company do. I will not write the hold page in Zona's actual report that deal with the patent warnings, too long. I am not a lawyer patent. But, even Amgen's Epogen a very complex compound is being challenged by Transkaryotic (and they have their focus in other complex drugs like insulin and growth hormone). Again, if Zona's patent holds, Vivus will too (good). I will not put my money in neither just base on their patents. In the short term this matter little. Long term it will be important. Respectfully, cacaito

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next